Related Experiment Video

Updated: May 5, 2026

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

2.8K

Stage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?

Brent N Reed, Carla A Sueta1

  • 1Center for Heart & Vascular Care, University of North Carolina, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599-7075, USA. carla_sueta@med.unc.edu.

Current Cardiology Reviews
|November 21, 2013
PubMed

Insights

Management strategies for asymptomatic left ventricular dysfunction (ALVD) are limited. Angiotensin converting enzyme inhibitors, beta blockers, statins, and implantable cardioverter defibrillators show promise in improving outcomes for high-risk patients.

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Patients with American College of Cardiology/American Heart Association (ACC/AHA) Stage B heart failure, or asymptomatic left ventricular dysfunction (ALVD), face a high risk of symptomatic heart failure.
  • Limited management strategies effectively slow disease progression or improve long-term outcomes in this population.

Purpose of the Study:

  • To review current evidence on management strategies for patients with ALVD.
  • To identify therapies that may improve clinical outcomes and reduce morbidity/mortality in this high-risk group.

Main Methods:

  • Review of pharmacologic therapies including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and beta blockers.
  • Evaluation of the role of statins in patients with a history of myocardial infarction.
  • Assessment of device-based therapies such as automatic implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT), and biventricular pacing.

Main Results:

  • ACE inhibitors are proven to improve clinical outcomes in ALVD. Beta blockers are generally recommended, particularly for ischemic etiology.
  • Statins demonstrate benefits in reducing major adverse cardiovascular events and heart failure events post-myocardial infarction.
  • ICDs reduce mortality in ALVD due to ischemic cardiomyopathy; CRT/biventricular pacing may benefit specific subgroups.

Conclusions:

  • While ACE inhibitors are established, beta blockers, statins, and device therapies like ICDs offer significant potential benefits for managing ALVD.
  • Further research and individualized treatment approaches are crucial for optimizing care in patients with asymptomatic left ventricular dysfunction.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Related Concept Videos

Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
564
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635